Pangenomic Health Inc. announced that its Chief Technology Officer, Colin Quon, has been appointed CTO of MUJN Diagnostics and will cease his role as CTO of PanGenomic Health effective immediately. Mr. Quon's focus as CTO will be on the development of the MUJN Diagnostic Support System, previously announced by the Company on March 22, 2023. The Company is also pleased to confirm that Maryam Marissen has been appointed a Director of the Company.

Ms. Marissen has been CEO of PanGenomic Health since September 2022. Prior to joining PanGenomic Health, Ms. Marissen served as Chief Executive Officer at Doseology Sciences from 2021-2022.